Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Adagene Inc. - ADS, each representing 1.25 ordinary shares
(NQ:
ADAG
)
3.660
-0.160 (-4.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Adagene Inc. - ADS, each representing 1.25 ordinary shares
< Previous
1
2
3
4
5
Next >
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
April 17, 2026
From
Adagene Inc.
Via
GlobeNewswire
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
April 14, 2026
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
April 02, 2026
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
April 02, 2026
From
Adagene Inc.
Via
GlobeNewswire
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic
↗
July 15, 2025
Via
Stocktwits
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
April 02, 2026
From
Adagene Inc.
Via
GlobeNewswire
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
April 01, 2026
From
Adagene Inc.
Via
GlobeNewswire
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
March 17, 2026
From
Adagene Inc.
Via
GlobeNewswire
Top movers in Wednesday's session
↗
March 11, 2026
Via
Chartmill
Adagene to Participate in Two Upcoming Investor Conferences
February 17, 2026
From
Adagene Inc.
Via
GlobeNewswire
Adagene Provides Business Update and 2026 Objectives
January 23, 2026
From
Adagene Inc.
Via
GlobeNewswire
These stocks are gapping in today's session
↗
December 16, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session.
Via
Chartmill
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
December 16, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
November 13, 2025
From
Adagene Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 11, 2025
Via
Benzinga
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
October 31, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
September 16, 2025
From
Adagene Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 09, 2025
Via
Benzinga
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
September 05, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
September 03, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Participate in Two Investor Conferences in September
August 26, 2025
From
Adagene Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 14, 2025
Via
Benzinga
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
August 12, 2025
From
Adagene Inc.
Via
GlobeNewswire
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
August 06, 2025
Via
Benzinga
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
July 15, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
July 08, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene announces up to $25 million strategic investment from Sanofi
July 01, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene to Present at Jefferies Global Healthcare Conference 2025
May 27, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2025
From
Adagene Inc.
Via
GlobeNewswire
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
April 28, 2025
From
Adagene Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
